349 related articles for article (PubMed ID: 33505469)
1. Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells.
Sávio-Silva C; Beyerstedt S; Soinski-Sousa PE; Casaro EB; Balby-Rocha MTA; Simplício-Filho A; Alves-Silva J; Rangel ÉB
Stem Cells Int; 2020; 2020():8833725. PubMed ID: 33505469
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.
Habiba UE; Khan N; Greene DL; Shamim S; Umer A
J Mol Med (Berl); 2024 Apr; 102(4):537-570. PubMed ID: 38418620
[TBL] [Abstract][Full Text] [Related]
3. The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.
Griffin TP; Martin WP; Islam N; O'Brien T; Griffin MD
Curr Diab Rep; 2016 May; 16(5):42. PubMed ID: 27007719
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus.
Davey GC; Patil SB; O'Loughlin A; O'Brien T
Front Endocrinol (Lausanne); 2014; 5():86. PubMed ID: 24936198
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic role of mesenchymal stem cells (MSCs) in diabetic kidney disease (DKD).
Xu N; Liu J; Li X
Endocr J; 2022 Oct; 69(10):1159-1172. PubMed ID: 35858781
[TBL] [Abstract][Full Text] [Related]
6. Impact of Diabetes Mellitus on Human Mesenchymal Stromal Cell Biology and Functionality: Implications for Autologous Transplantation.
Mahmoud M; Abu-Shahba N; Azmy O; El-Badri N
Stem Cell Rev Rep; 2019 Apr; 15(2):194-217. PubMed ID: 30680660
[TBL] [Abstract][Full Text] [Related]
7. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis.
Maria AT; Toupet K; Maumus M; Fonteneau G; Le Quellec A; Jorgensen C; Guilpain P; Noël D
J Autoimmun; 2016 Jun; 70():31-9. PubMed ID: 27052182
[TBL] [Abstract][Full Text] [Related]
8. Administration of mesenchymal stem cells in diabetic kidney disease: mechanisms, signaling pathways, and preclinical evidence.
Zhu Y; Luo M; Bai X; Lou Y; Nie P; Jiang S; Li J; Li B; Luo P
Mol Cell Biochem; 2022 Aug; 477(8):2073-2092. PubMed ID: 35469057
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody.
Liew A; Baustian C; Thomas D; Vaughan E; Sanz-Nogués C; Creane M; Chen X; Alagesan S; Owens P; Horan J; Dockery P; Griffin MD; Duffy A; O'Brien T
Cell Transplant; 2018 Aug; 27(8):1210-1221. PubMed ID: 30016879
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
Helou N; Dwyer A; Shaha M; Zanchi A
JBI Database System Rev Implement Rep; 2016 Jul; 14(7):169-207. PubMed ID: 27532796
[TBL] [Abstract][Full Text] [Related]
11. Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro.
Davies LC; Alm JJ; Heldring N; Moll G; Gavin C; Batsis I; Qian H; Sigvardsson M; Nilsson B; Kyllonen LE; Salmela KT; Carlsson PO; Korsgren O; Le Blanc K
Stem Cells Transl Med; 2016 Nov; 5(11):1485-1495. PubMed ID: 27412884
[TBL] [Abstract][Full Text] [Related]
12. Effects of Mesenchymal Stem Cells Therapy on Cardiovascular Risk Factors in Experimental Diabetic Kidney Disease.
Hussein EN; Hamed GM; Seif AA; Ahmed MA; Abu Zahra FAE
Can J Kidney Health Dis; 2020; 7():2054358120957429. PubMed ID: 33149923
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Immune Responses Exerted Following Syngeneic, Allogeneic, and Xenogeneic Transplantation of Mesenchymal Stem Cells into the Mouse Brain.
Hwang JW; Lee NK; Yang JH; Son HJ; Bang SI; Chang JW; Na DL
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357509
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.
Pigott JH; Ishihara A; Wellman ML; Russell DS; Bertone AL
Vet Immunol Immunopathol; 2013 Nov; 156(1-2):99-106. PubMed ID: 24094688
[TBL] [Abstract][Full Text] [Related]
15. Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models.
Torres Crigna A; Daniele C; Gamez C; Medina Balbuena S; Pastene DO; Nardozi D; Brenna C; Yard B; Gretz N; Bieback K
Front Med (Lausanne); 2018; 5():179. PubMed ID: 29963554
[TBL] [Abstract][Full Text] [Related]
16. From "Bench to Bedside": Current Advancement on Large-Scale Production of Mesenchymal Stem Cells.
Bunpetch V; Wu H; Zhang S; Ouyang H
Stem Cells Dev; 2017 Nov; 26(22):1662-1673. PubMed ID: 28934885
[TBL] [Abstract][Full Text] [Related]
17. Complement C5a induces mesenchymal stem cell apoptosis during the progression of chronic diabetic complications.
Zhu M; He X; Wang XH; Qiu W; Xing W; Guo W; An TC; Ao LQ; Hu XT; Li Z; Liu XP; Xiao N; Yu J; Huang H; Xu X
Diabetologia; 2017 Sep; 60(9):1822-1833. PubMed ID: 28577176
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives.
Li H; Zhu H; Ge T; Wang Z; Zhang C
Stem Cell Rev Rep; 2021 Oct; 17(5):1552-1569. PubMed ID: 33675006
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Stem Cell Application in Diabetes Mellitus: Promising Future Therapy for Diabetes and Its Complications.
Bani Hamad FR; Rahat N; Shankar K; Tsouklidis N
Cureus; 2021 Feb; 13(2):e13563. PubMed ID: 33815977
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic.
Zhou JY; Zhang Z; Qian GS
Cell Death Discov; 2016; 2():16055. PubMed ID: 27551543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
